Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.

[1]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[2]  L. Qin,et al.  Targeting the osteosarcoma cancer stem cell , 2010, Journal of orthopaedic surgery and research.

[3]  Yingjie Yu,et al.  The Wnt/β-catenin pathway regulates growth and maintenance of colonospheres , 2010, Molecular Cancer.

[4]  Eleonora Petrucci,et al.  The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. , 2010, Blood cells, molecules & diseases.

[5]  Michael Kahn,et al.  Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells? , 2010, Clinical Cancer Research.

[6]  N. Agarwal,et al.  CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. , 2010, Cancer research.

[7]  G. Opelz,et al.  Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. , 2010, Biochemical and biophysical research communications.

[8]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[9]  S. S. Koh,et al.  Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. , 2009, International journal of oncology.

[10]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[11]  D. Steindler,et al.  Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. , 2009, Cancer research.

[12]  V. Nurcombe,et al.  Wnt signaling controls the fate of mesenchymal stem cells. , 2009, Gene.

[13]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[14]  Herrick J Siegel,et al.  Current concepts on the surgical and medical management of osteosarcoma , 2008, Expert review of anticancer therapy.

[15]  A. Burger,et al.  Cancer stem cell targeted agents: therapeutic approaches and consequences. , 2008, Current opinion in molecular therapeutics.

[16]  P. Chambon,et al.  Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling , 2008, Nature.

[17]  Song Jin,et al.  Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases , 2008, Acta Pharmacologica Sinica.

[18]  H. Immervoll,et al.  Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. , 2007, Neoplasia.

[19]  Wei-wei Su,et al.  Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines , 2007, Acta Pharmacologica Sinica.

[20]  Edward W Scott,et al.  Stem-like cells in bone sarcomas: implications for tumorigenesis. , 2005, Neoplasia.

[21]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[22]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[24]  W. Akeson,et al.  Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. , 1993, Cancer research.